Pharmacology and Therapeutics

Risks of ACE Inhibitor and ARB Usage in COVID‐19: Evaluating the Evidence

1. Krishna Sriram
2. Paul A. Insel

Reviewed by ScreenIT

A Review of Dosages of Chloroquine and Hydroxychloroquine for COVID-19 in registered Clinical Trials during First Quarter of 2020

1. Divya RSJB Rana
2. Santosh Dulal

Reviewed by ScreenIT

The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis

1. James A Watson
2. Robert J Commons
3. Joel Tarning
4. Julie A Simpson
5. Alejandro Llanos Cuentas
6. Marcus VG Lacerda
7. Justin A Green
8. Gavin CKW Koh
9. Cindy S Chu
10. François H Nosten
11. Richard N Price
12. Nicholas PJ Day
13. Nicholas J White

• Curated by eLife

  eLife assessment

  This competently performed retrospective analysis presents important findings concerning the clinical use of tafenoquine, a drug against Plasmodium vivax malaria. The assembly of the majority of global tafenoquine pharmacology data from clinical treatment studies provides compelling evidence in support of the drug's regimen that includes an increase in dosing, which would lead to a significant enhancement of the drug efficacy, hence a decrease in recurrent parasitemia. The manuscript could benefit from a more detailed analysis and discussion concerning the side effects of the drug affecting more susceptible populations.

Reviewed by eLife

Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study

1. Carlos K H Wong
2. Ivan C H Au
3. Kristy T K Lau
4. Eric H Y Lau
5. Benjamin J Cowling
6. Gabriel M Leung

Reviewed by ScreenIT

Hyperbaric Oxygen for Treatment of Long COVID Syndrome (HOT-LoCO); Protocol for a Randomised, Placebo-Controlled, Double-Blind, Phase II Clinical Trial

1. Anders Kjellberg
2. Lina Abdel-Halim
3. Adrian Hassler
4. Sara El Gharbi
5. Sarah Al-Ezerjawi
6. Emil Boström
7. Carl Johan Sundberg
8. John Pernow
9. Koshiar Medson
10. Jan Kowalski
11. Kenny A Rodriguez-Wallberg
12. Xiaowei Zheng
13. Sergiu-Bogdan Catrina
14. Michael Runold
15. Marcus Ståhlberg
16. Judith Bruchfeld
17. Malin Nygren-Bonnier
18. Peter Lindholm

Reviewed by ScreenIT

Cannabis potential effects to prevent or attenuate SARS-COV2 contagion

1. M. Herrera-Gómez Paula
2. F. Echeverri-Cataño Luis
3. S Giraldo
4. Y Ruiz Colorado-
5. Alberto Vélez van Meerbeke

Reviewed by ScreenIT

Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy

1. Marco Cosentino
2. Veronica Vernocchi
3. Stefano Martini
4. Franca Marino
5. Barbara Allasino
6. Maria Antonietta Bàlzola
7. Fabio Burigana
8. Alberto Dallari
9. Carlo Servo Florio Pagano
10. Antonio Palma
11. Mauro Rango
12. on behalf of IppocrateOrg Association Working Group for the Early Outpatient Treatment of COVID-19

Reviewed by ScreenIT

Pharmacokinetics of favipiravir in adults with mild COVID-19 in Thailand

1. Weerawat Manosuthi
2. Ing-orn Prasanchaimontri
3. Suvimol Niyomnaitham
4. Rujipas Sirijatuphat
5. Lantharita Charoenpong
6. Katherine Copeland
7. Tim R. Cressey
8. Phongpan Mokmued
9. Kulkanya Chokephaibulkit

Reviewed by ScreenIT

Clinical and Non-clinical Proof of Concept Supporting the Development of RJX As an Adjunct to Standard of Care Against Severe COVID-19

1. Fatih M. Uckun
2. Muhammad Saeed
3. Mustafa Awili
4. Ibrahim H. Ozercan
5. Sanjive Qazi
6. Cynthia Lee
7. Adeel Shibli
8. Alan W. Skolnick
9. Alonso Prusmack
10. Joseph Varon
11. Cesar I.P. Barrera
12. Cemal Orhan
13. Michael Volk
14. Kazim Sahin

Reviewed by ScreenIT

Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19

1. Eunjin Hong
2. Lisa M. Almond
3. Peter S. Chung
4. Adupa P. Rao
5. Paul M. Beringer

Reviewed by ScreenIT